S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
New CBOE “special perk” helps traders target income every weekend (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
New CBOE “special perk” helps traders target income every weekend (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
New CBOE “special perk” helps traders target income every weekend (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
New CBOE “special perk” helps traders target income every weekend (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?

Deciphera Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DCPH)

$14.80
-0.27 (-1.79%)
(As of 12/8/2023 ET)
Compare
Today's Range
$14.78
$15.46
50-Day Range
$10.11
$15.07
52-Week Range
$9.90
$22.76
Volume
975,080 shs
Average Volume
565,813 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.56

Deciphera Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
52.4% Upside
$22.56 Price Target
Short Interest
Bearish
11.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.37
Upright™ Environmental Score
News Sentiment
0.33mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$369,730 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.34) to ($2.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

256th out of 941 stocks

Pharmaceutical Preparations Industry

93rd out of 440 stocks


DCPH stock logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock Price History

DCPH Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals Inc DCPH
Positive Report for Deciphera Pharmaceuticals (DCPH) from JonesTrading
Deciphera Pharma Tumor Drug Trial Meets Endpoints
Deciphera Pharmaceuticals Pipeline Is Underwhelming
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.56
High Stock Price Target
$30.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+52.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-178,930,000.00
Net Margins
-127.92%
Pretax Margin
-127.45%

Debt

Sales & Book Value

Annual Sales
$134.04 million
Book Value
$5.05 per share

Miscellaneous

Free Float
76,574,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
0.50
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Steven L. Hoerter (Age 52)
    President, CEO & Director
    Comp: $1.24M
  • Dr. Daniel L. Flynn Ph.D. (Age 68)
    Senior Advisor & Founder
    Comp: $759.18k
  • Mr. Thomas Patrick Kelly J.D.Mr. Thomas Patrick Kelly J.D. (Age 52)
    Executive VP, CFO & Treasurer
    Comp: $778.85k
  • Mr. Daniel C. Martin (Age 48)
    Senior VP & Chief Commercial Officer
    Comp: $711.42k
  • Dr. Matthew L. Sherman M.D. (Age 67)
    Executive VP & Chief Medical Officer
    Comp: $865.62k
  • Dr. Kevin Brodbeck Ph.D.
    Senior VP & Chief Technical Officer
  • Dr. Dashyant Dhanak Ph.D. (Age 62)
    Executive VP & Chief Scientific Officer
  • Jennifer Larson
    Senior Vice President of Finance & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Senior VP & General Counsel
  • Ms. Lisa Amaya Price
    Senior VP & Chief Human Resources Officer














DCPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price target for 2024?

10 equities research analysts have issued 12-month price targets for Deciphera Pharmaceuticals' shares. Their DCPH share price targets range from $9.00 to $30.00. On average, they anticipate the company's share price to reach $22.56 in the next twelve months. This suggests a possible upside of 52.4% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2023?

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of 2023. Since then, DCPH shares have decreased by 9.7% and is now trading at $14.80.
View the best growth stocks for 2023 here
.

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,550,000 shares, an increase of 41.9% from the October 31st total of 3,910,000 shares. Based on an average daily volume of 644,300 shares, the days-to-cover ratio is presently 8.6 days. Currently, 11.5% of the company's stock are sold short.
View Deciphera Pharmaceuticals' Short Interest
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings results on Monday, October, 30th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.03. The business earned $43.31 million during the quarter, compared to analysts' expectations of $39.66 million. Deciphera Pharmaceuticals had a negative net margin of 127.92% and a negative trailing twelve-month return on equity of 49.41%. During the same period in the prior year, the company earned ($0.55) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (8.61%), Armistice Capital LLC (5.76%), Redmile Group LLC (5.59%), Braidwell LP (4.16%), Morgan Stanley (1.99%) and Assenagon Asset Management S.A. (1.01%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DCPH) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -